NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you experienced a loss from your investment in GSK plc (NYSE:GSK) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135610&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you experienced a loss from your investment in GSK plc (NYSE:GSK) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135563&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, has informed investors about a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE:GSK) and some of its executives. Class Definition This lawsuit aims to seek compensation for alleged breaches of federal securities laws on behalf of all individuals and entities that bought or acquired GSK American Depositary Receipts ("ADRs") from February 5, 2020, to August 14, 2022, inclusive (the "Class Period").
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you experienced a loss from your investment in GSK plc (NYSE:GSK) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135381&wire=1 or reach out to Joseph E. Levi, Esq.
LOS ANGELES, March 11, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP has announced that investors who have experienced losses can take the lead in a class action lawsuit for securities fraud against GSK plc. ("GSK" or the "Company") (NYSE: GSK).
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you experienced a loss from your investment in GSK plc (NYSE:GSK) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135280&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you experienced a loss from your investment in GSK plc (NYSE:GSK) and are interested in finding out about possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135188&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, has announced that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and some of its executives. Class Definition This lawsuit aims to seek compensation for damages due to alleged breaches of federal securities laws on behalf of all individuals and entities that bought or acquired GSK American Depositary Receipts ("ADRs") from February 5, 2020, to August 14, 2022, inclusive (the "Class Period").
NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP has announced that a class action lawsuit has been initiated against GSK plc ("GSK" or the "Company") (NYSE: GSK). Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, or toll-free at 888.4-POMLAW, Ext.
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you experienced a loss from your investment in GSK plc (NYSE:GSK) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=135127&wire=1 or reach out to Joseph E. Levi, Esq.